Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Berinert | C1 Esterase Inhibitor (Human) | CSL Behring | A-125287 RX | 2009-10-09 | 1 products |
Cinryze | C1 Esterase Inhibitor (Human) | Takeda | A-125267 RX | 2008-10-10 | 1 products |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Haegarda | C1 Esterase Inhibitor Subcutaneous (Human) | CSL Behring | A-125606 RX | 2017-06-22 | 2 products |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hereditary angioedemas | D054179 | EFO_0004131 | — | 3 | 3 | 5 | 1 | 1 | 10 |
Angioedema | D000799 | EFO_0005532 | T78.3 | 2 | 2 | 5 | 1 | 1 | 9 |
Hereditary angioedema types i and ii | D056829 | — | — | 2 | 1 | 2 | 1 | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney transplantation | D016030 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | Conestat alfa |
INN | conestat alfa |
Description | Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas. |
Classification | Protein |
Drug class | enzyme inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2108350 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06404 |
UNII ID | 5QS67N4551 (ChemIDplus, GSRS) |